Overview
An Evolution in Microbiota Restoration: Approaches and Results in C. difficile
Earn complimentary CME Credit
Registration is closed for this activity.
Join us for a live virtual symposium with an expert faculty panel as they discuss microbiota restoration therapy for C. difficile infection. Topics will include a comprehensive review of the evolution of fecal microbiota transplantation for C. difficile infection and a look into the next frontier of microbiota restoration therapies. Faculty will contextualize these results and discuss what the next year may look like.
Physicians, ID specialists, hospitalists, internists, pharmacists, and other healthcare professionals who care for patients at risk of serious infection.
C. difficile recurrence continues to pose significant burdens on patients, clinicians, and the healthcare system. Clinicians must be familiar with microbiota restoration therapies currently under investigation that can reduce complications and improve patient outcomes. This activity will review the emerging pipeline of microbiota restoration therapies and the impact this may have on C. difficile infection in the next year.
Upon completion of this activity, participants will be able to:
• Evaluate the role of the gut microbiome in relationship to C. difficile infection and approaches to restoration for prevention of recurrent infection
• Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
• Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
• Evaluate the role of the gut microbiome in relationship to C. difficile infection and approaches to restoration for prevention of recurrent infection
• Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
• Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
• Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Ferring Pharmaceuticals, Inc.
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Sahil Khanna, MD, MBBS, MS, FACG
Associate Professor of Medicine
Gastroenterology and Hepatology
Mayo Clinic
Rochester, MN
Gautam Mankaney, MD
Department of Gastroenterology and Hepatology
The Cleveland Clinic
Cleveland, OH
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
The following financial relationships have been provided:
Paul Feuerstadt, MD, FACG, AGAF
Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Roche Diagnostics
Speakers' Bureau: Merck and Company
Sahil Khanna, MBBS, MS
Sources of Funding for Research: Ferring Pharmaceuticals, Inc., Rebiotix, Inc
Consulting Agreements: Facile Therapeutics, Inc., Premier Inc., Probiotech LLC, Shire PLC
Gautam Mankaney, MD
Nothing to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit, participants are required to participate in the live activity and complete the posttest, and evaluation. At the end of the activity, participants will be provided instructions to receive their certificate. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.